Russell Hanson is the Senior Director for Research at the McSilver Institute’s AI Hub. He has been working in artificial intelligence since 2005, first at MIT and Harvard Medical School where he was conducting basic research into cancer progression and resistance.
Hanson came to New York City to join the faculty at the Icahn School of Medicine at Mount Sinai, leading a research lab and publishing on applications of artificial intelligence and data science in neurodegenerative disease and Alzheimer’s disease. He has had a long career applying AI to problems in health, medicine, and data science, starting at Harvard Medical School and the Boston Children’s Hospital, where he researched artificial intelligence systems for cancer vaccines and cancer biomarker prediction.
Most recently Hanson served as Chief Scientific Officer at two AI firms directing dynamic research programs and researchers employing state-of-the-art techniques to solve outstanding automation problems for Fortune 500 companies. Russell and his collaborators have published well-received papers in Nature journals on the applications of AI in neurodegenerative disease, the use of AI to help small businesses, and other ways current AI technologies can have an immediate impact.
He received a B.S. degree from Reed College and an M.S. degree from Georgia Tech. His PhD work was in chemistry at Boston University, and his postdoc work took place at the Danish Technical University.